Small Cell Lung Cancer Highlights From IASLC 2021

Ramaswamy Govindan, MD


October 04, 2021

Studies focused on the use of lurbinectedin in treatment of relapsed and pretreated patients top the highlighted findings in small cell lung cancer (SCLC) presented at the 2021 World Conference on Lung Cancer.

Dr Ramaswamy Govindan, director of the Department of Medical Oncology at Washington University Medical School, first discusses the phase 3 ATLANTIS trial, which looked at lurbinectedin in combination with doxorubicin vs standard care in relapsed SCLC patients. Comparable efficacy results were observed in both arms, but the safety and tolerability profile for lurbinectedin/doxorubicin was found to be superior.

Dr Govindan then shares an abstract that looked at subsequent systemic therapy after lurbinectedin discontinuation in patients with SCLC, followed by a study looking at lurbinectedin in pretreated patients with SCLC and mesothelioma.

Next, he discusses a paper from Memorial Sloan Kettering that looked at a single-cell atlas of SCLC patients' tumors. The key finding was that expression of a gene called PLCG2 across various types of SCLC was associated with increased metastasis as well as increased levels of monocytes, which may dampen the immune response.

Finally, Dr Govindan offers insight on a phase 1b/2 study that looks at autologous dendritic cell vaccination in combination with atezolizumab in patients with SCLC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.